Worth Venture Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Worth Venture Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-132,900	Closed	-$184K	–	160
2017 Q1	$184K	Buy	132,900 +123,100	+1,256%	+$1.94M	0.16%	99
2016 Q4	$34K	Buy	+9,800	New	+$127K	0.04%	110

Other funds holding PRTK

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Worth Venture Partners's PRTK Position: Q2 2023 in Review

Worth Venture Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 657,885 shares — an estimated $1.67M sold.

Worth Venture Partners first reported a position in PRTK in Q4 2016 and held it in 13 quarters. The position peaked at $2.5M in Q4 2021. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Worth Venture Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Worth Venture Partners sold 657,885 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $1.67M.
Worth Venture Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 13 quarters.
Worth Venture Partners's Paratek Pharmaceuticals, Inc. position peaked at $2.5M in Q4 2021.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.